Hospitals urge regulators to halt drugmakers’ expanded 340B data policies

Emily Olsen / healthcaredive - The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.

AI Summary: Hospitals and provider groups are urging federal regulators to halt new drugmaker policies that expand claims-data reporting tied to 340B discounts, calling the requirements unlawful and administratively burdensome. The dispute pits safety-net providers against manufacturers seeking program transparency — a classic tug-of-war with patients’ financial stakes caught in the middle.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Optum Rx/Caremark and FTC edge toward settlement in insulin case / 2 months

340B discounts face reform as profits outpace patient benefit / 5 wks

AbbVie sues HHS over 340B patient definition and guidance / 7 wks

CVS sues Tennessee over PBM‑pharmacy separation law / 4 days

One in three Americans cut expenses to afford healthcare / 2 months

Judge orders Leapfrog to remove safety grades for five Florida hospitals / 2 months

AbbVie sues over Botox selection in Medicare price negotiations / 3 months